There is immense scope and interest in the development of photocatalytic CO2 conversion. We have successfully developed a new supramolecular photocatalyst (Ir–Rh) in which the Ir(III) complex Ir(piq)2(BL)+ (piq = 1-phenylisoquinoline, BL = 1,2-bis(4′-methyl2,2′-bipyridin-4-yl)ethane) as a photosensitizer and the Rh(III) complex Rh(BL)(Cp*)Cl+ (Cp* = 1,2,3,4,5-pentamethylcyclopentadienyl) as the catalyst are connected by a bridging ligand BL. The photophysical properties and the redox behavior of all complexes were investigated. Ir–Rh efficiently photocatalyzed CO2 reduction in the presence of 1-benzyl-1,4-dihydronicotinamide (BNAH) as the sacrificial electron donor, selectively yielding formic acid as the major product (SHCOOH > 90%) with minor amounts of CO and H2. However, the combined system of the corresponding mononuclear complexes produced a smaller amount of formic acid. The mechanism of the photocatalytic reaction was explored through in situ UV–vis absorption studies and electrochemical measurements.
Gotgi et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: